The Role of NT-proBNP as a Biomarker in Evaluating Residual Cardiovascular Risk in 200 Type 2 DM Patients Optimized for Conventional CV Risk Markers over Two Years

被引：0
|
作者：
Gupta, Vishal
Teli, Vaishali
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-1513-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 29 条
  • [21] Cardiovascular risk in ten years of type 2 DM patients in first preventive situation derived to specialized care. Does gender difference exist?
    Ostmann, Olga
    Witte, Jillian
    Hudson, Terica
    Erickson, Judi
    Larsen, Jennifer
    DIABETES, 2008, 57 : A611 - A612
  • [22] Saxagliptin (SAXA) Reduces A1C and Is Well Tolerated in Patients With Type 2 Diabetes (T2DM) and High Framingham 10-Year Cardiovascular (CV) Risk
    Bonora, Enzo
    Allen, Elsie
    Bryzinski, Brian
    Hirshberg, Boaz
    Cook, William
    DIABETES, 2013, 62 : A295 - A295
  • [23] Do We Need More than One Biomarker for Risk Prediction in Acute Dyspnea? Concentrations of ST2 Strongly Predict 4 Year Prognosis in Acutely Dyspneic Patients with Very Low NT-proBNP Values
    van Kimmenade, Roland R.
    Rehman, Shafiq
    Januzzi, James L., Jr.
    CIRCULATION, 2008, 118 (18) : S866 - S867
  • [24] Urinary albumin and 8-oxo-7,8-dihydroguanosine as markers of mortality and cardiovascular disease during 19 years after diagnosis of type 2 diabetes - A comparative study of two markers to identify high risk patients
    Broedbaek, Kasper
    Koster-Rasmussen, Rasmus
    Siersma, Volkert
    Persson, Frederik
    Poulsen, Henrik E.
    Olivarius, Niels de Fine
    REDOX BIOLOGY, 2017, 13 : 363 - 369
  • [25] Cardiovascular risk factors control in Polish patients with type 2 diabetes within the first two years of diagnosis: results of the ARETAEUS1 study
    Bala, Malgorzata M.
    Lesniak, Wiktoria
    Placzkiewicz-Jankowska, Ewa
    Topor-Madry, Roman
    Jaeschke, Roman
    Sieradzki, Jacek
    Grzeszczak, Wladyslaw
    Banasiak, Waldemar
    KARDIOLOGIA POLSKA, 2011, 69 (12) : 1249 - 1257
  • [26] Initial treatment with rosiglitazone (RSG) and glimepiride (GLIM) fixed-dose combination (FDC) reduces cardiovascular risk markers and improves insulin sensitivity in patients with type 2 diabetes (T2DM)
    Goldstein, Barry J.
    Segiet, Thomas S. E.
    Ferreira-Cornwell, Celeste
    Krebs, Jacqueline B.
    Chou, Hubert S.
    DIABETES, 2006, 55 : A113 - A113
  • [27] Progression of glycaemia and cardiovascular risk factors in patients of different age groups with new type 2 diabetes over 5 years of follow-up in a diabetes quality improvement initiative
    Coppell, Kirsten J.
    Lee, Janet
    Williams, Sheila M.
    Mann, Jim I.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 93 (03) : 357 - 362
  • [28] ESTIMATED EVENTS AVOIDED AND COST OFFSETS ASSOCIATED WITH USING CANAGLIFLOZIN TO TREAT PATIENTS WITH TYPE TWO DIABETES MELLITUS (T2DM) WITH OR AT HIGH RISK OF DEVELOPING CARDIOVASCULAR DISEASE (CVD) IN ENGLAND
    Sanchez, Garcia J. J.
    Willis, M.
    Nilsson, A.
    Ericson, O.
    Ball, P.
    Dunlop, W.
    VALUE IN HEALTH, 2018, 21 : S127 - S127
  • [29] A Retrospective Study of 6-Month Reduction in Risk of Developing Cardiovascular Diseases and Type 2 Diabetes Mellitus in Severely Obese Patients Over 60 Years of Age Following Bariatric Surgery
    Domienik-Karlowicz, Justyna
    Ziemianski, Pawel
    Malkowski, Piotr
    Kosieradzki, Maciej
    Pruszczyk, Piotr
    Lisik, Wojciech
    MEDICAL SCIENCE MONITOR, 2019, 25 : 2577 - 2582
123